Buoyed by recent state-level opioid settlements, Teva’s president and CEO Kåre Schultz is “slightly more optimistic on the time schedule now” for a potential deal spanning the whole of the US. “I hope that we will see a nationwide settlement before the end of this year,” Schultz has declared.
Teva Puts End Of 2022 Ambition On Nationwide US Opioids Settlement
‘We Believe We’re Getting Closer,’ Says CEO Kåre Schultz
After adding more than $1bn to its legal settlement contingency in Q1, Teva has given its clearest indication yet for when it expects to announce a nationwide deal in the US to settle opioid-related claims. The Israeli firm is facing two bench trials in the coming weeks and months but is optimistic on that front also.
